“Six Minute Walk Test” From StatPearls

Today, I review, link to, and excerpt from StatPearls’ Six Minute Walk Test. Harold A. Matos Casano; Fatima Anjum. Last Update: August 14, 2023.

Here are some of the references:

Britto RR, Probst VS, de Andrade AF, Samora GA, Hernandes NA, Marinho PE, Karsten M, Pitta F, Parreira VF. Reference equations for the six-minute walk distance based on a Brazilian multicenter study. Braz J Phys Ther. 2013 Nov-Dec;17(6):556-63. [PMC free article] [PubMed]
Chetta A, Zanini A, Pisi G, Aiello M, Tzani P, Neri M, Olivieri D. Reference values for the 6-min walk test in healthy subjects 20-50 years old. Respir Med. 2006 Sep;100(9):1573-8. [PubMed]
Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1384-7. [PubMed]

All that follows is from the above resource.


There are a number of field walking tests designed to measure the exercise capacity of patients with chronic respiratory disease. Among these, the 6-minute walk test (6MWT) is a key study providing a functional, therapeutic response, and prognostic data that is valuable in the care of patients with respiratory as well as cardiac diseases. It is used widely due to its simplicity and reproducibility, delivering a consolidated image of the cardiopulmonary and musculoskeletal response to exercise. It requires no special training on the part of the staff performing it, items and equipment available at any clinician’s office or hospital may be used, and is safe and well-tolerated by most patients at any stage of disease, with the test being highly reflective of usual daily activity and exercise performance.

It is particularly useful in assessing and monitoring chronic obstructive pulmonary disease (COPD) and has a role in managing patients with other conditions, including those with diffuse parenchymal lung diseases and pulmonary arterial hypertension. Overall, it is an inexpensive test that can provide a wealth of data with potential impact on the treatment of several conditions. The test is self-paced, with standardized instructions and encouragement being given as patients walk as far as possible over 6 minutes through a flat corridor. The final distance is recorded in meters.

Anatomy and Physiology

The interactions between the lungs and heart during exercise are the main physiological phenomena relevant to the test. In general terms, deoxygenated blood returning to the right heart via the venous circulation is pumped by the right ventricle into the pulmonary artery. As it advances through the pulmonary capillaries, gas exchange occurs when the capillaries meet the alveoli, with oxygen entering the circulation while carbon dioxide is released into the alveoli.

Oxygenated blood then circulates to the left heart, where the left ventricle pumps it to the systemic circulation, through which it is eventually delivered to the organs to sustain aerobic metabolism. The neurological and musculoskeletal systems are also involved in this process, particularly with concern to the process of matching minute ventilation to cardiac output in response to varying exercise intensity levels. This occurs via reflex responses that adjust the cardiac and pulmonary activity to the oxygen consumption levels required by the degree of exertion. Impairment of any of these components, the cardiac, pulmonary, neurological, or musculoskeletal systems, will decrease exercise tolerance.


The 6MWT is primarily indicated for assessing the response to treatment in moderate-to-severe cardiac or pulmonary disease. It can also serve for preoperative risk stratification. For example, patients walking less than 70% of their predicted distance during preoperative assessment for pulmonary surgery had a higher risk of postoperative pulmonary complications.

Other guideline-based indications for the 6MWT include its use to measure a patient’s exercise tolerance and prognosis depending on the underlying condition. Since there are many organ systems involved during physical activity, the 6MWT can be used to assess conditions specifically affecting any of these. Among pulmonary diseases, the 6MWT has been widely used in patients with COPD.

Other conditions in which it can be helpful include idiopathic pulmonary fibrosis, cystic fibrosis, and sarcoidosis. Heart failure and peripheral artery disease are cardiovascular conditions with a significant burden of morbidity and mortality, where the 6MWT can be a useful adjunct in their assessment and management. It is often used in the context of cardiac rehabilitation, being reflective of clinical change.

Functional impairment resulting from conditions affecting the neurological and muscular systems, such as fibromyalgia, Parkinson disease, multiple sclerosis, and spinal muscular atrophy, can also be reliably evaluated with the 6MWT. Furthermore, it has been found to be highly predictive of ambulatory capacity after total knee arthroplasty.


The only established absolute contraindication to the 6MWT is having a history of an acute coronary syndrome (either unstable angina or myocardial infarction) within 30 days prior to the test. However, other absolute contraindications applied to field walking tests in general, such as syncope, acute respiratory failure, or the presence of a noncardiopulmonary condition that may impair or become exacerbated by exercise, should also be considered.

Relative contraindications include severe, uncontrolled hypertension and a resting heart rate greater than 120 beats per minute. While the 6MWT is self-paced, which would reduce the likelihood of untoward events resulting from otherwise excessive exercise levels, clinician judgment needs to be used when deciding to proceed with testing as with any other test.


At a minimum, the equipment required for the test should include a pulse oximeter, a portable oxygen device (to be used if needed by the patient), a chair, a validated dyspnea scale (e.g., the Borg scale), and a stopwatch. At least two small cones should be available to mark the turnaround points. An automated electric defibrillator should also be within reach. The test should be done in a comfortable space for the patient and allow accurate measurement of the distance walked.


Medical personnel who must be knowledgeable in the standard protocol for the 6MWT conducts the test. A minimum requirement for staff conducting the six-minute walk test is training in Basic Life Support. Finally, the presence of a physician during the test may be requested at the discretion of the laboratory medical director or the prescribing physician.


The following are directives relevant to the preparation for the test, based on statements by the European Respiratory Society and American Thoracic Society :

  • Comfortable clothing, including walking shoes, should be worn.
  • Patients should use any mobility aid device already needed to ambulate (e.g., a cane or walker).
  • Patients should continue with their usual medications.
  • Patients should rest for at least two hours before the test.
  • Perform successive tests at the same time of the day to maintain consistency.
  • Warm-ups are not allowed.
  • Lung function tests should be done at least 15 minutes before the walk test if scheduled on the same day.

Technique or Treatment

In general, the technician or other staff performing the test should observe the following steps:

  • The patient should rest for approximately 10 minutes before starting the test.
  • Measure the baseline heart rate and oxygen saturation. These should be continuously monitored to identify the lowest oxygen saturation, which may occur before the end of the test.
  • The patient’s baseline dyspnea is then rated using the Borg scale.
  • Set the lap counter and timer.
  • Provide the patient with detailed instructions on how to proceed during the test.
  • The patient is then positioned at the starting line and allowed to walk unassisted once the test begins.
  • The technician should only address the patient during the test. As each minute passes, the patient should be informed of the time left to complete the test and encouraged to continue.
  • At the end of the test, record the Borg dyspnea and fatigue levels, check heart rate and oxygen saturation, the number of laps from the counter or marks on the worksheet, and total distance walked.


When standard protocols are followed, complications are rare. As noted previously, the self-paced character of the test limits their occurrence. The most common adverse event reported in the literature is oxygen desaturation below 80% resulting in termination of the test. Chest pain and tachycardia have been reported much less frequently. In all, none of the reported adverse events resulted in long-term complications.

Clinical Significance

The primary test outcome is the final distance walked (6MWD). Among healthy individuals, the average 6MWD is between 400 and 700 meters. This range overlaps with data reported in other populations. Reference equations are available to determine the 6MWD percent predicted and lower limit of normal for adults.

Factors associated with variability in test performance among healthy subjects include weight and age. However, most of the variability remains unexplained. The longest distance walked by the patient should be taken as the actual result since there is a learning effect associated with improved walking distance when at least two tests are conducted. Other factors that may affect the 6MWD in healthy adults include the methodology for 6MWT and the percentage of peak heart rate achieved.

The 6MWT has limitations as a measure of exercise capacity that needs to be considered. Due to its nature, the study cannot identify the cause of dyspnea, or hypoxemia, or the mechanisms underlying a particular patient’s exercise intolerance. Additionally, it cannot determine peak oxygen uptake, though it correlates with this cardiopulmonary exercise test measurement in select patients.

In the absence of specific clinical clues or an established diagnosis, a low 6MWD is a non-specific finding. In such situations, the cause of the abnormal finding should be investigated, with attention to the cardiac, pulmonary, or musculoskeletal systems, as guided by the patient’s medical history.

The 6MWD has been established as a significant marker of disease severity for COPD patients since it directly correlates with lower quality of life indices, respiratory and functional impairment, and survival. It also reflects the clinical response to treatments such as lung volume reduction surgery. However, it does not have the same role for pharmacological interventions. For chronic lung diseases in general, the average 6MWD ranges between 300 and 450 meters. In COPD specifically, a 6MWD of 350 meters or less is inversely correlated with the risk of exacerbation, hospitalization, and mortality. In one study, the minimal difference in walking distance associated with a change in perceived clinical decline or improvement was a mean of 54 meters.

Other measures such as the body weight-walking distance product (D x W) have been proposed as alternative estimates of functional capacity in COPD patients. The DxW product correlates better with a patient’s actual work of walking, as well as maximal oxygen uptake and anaerobic threshold, compared to walking distance alone. However, its role in the care of adults with chronic respiratory disease remains undefined.

In idiopathic pulmonary fibrosis, the 6MWD is also an independent predictor of mortality. A baseline 6MWD under 250 meters, and a subsequent decline greater than 50 meters in 24 weeks, are associated with a two- and three-fold increase in mortality, respectively.

As noted, the 6MWT has also been validated for use in cardiovascular diseases. In heart failure, a condition associated with functional disability and exercise intolerance, both in a sense analogous to the impairment of daily activity observed among COPD patients; the 6MWT can provide reliable data about physiological reserve and prognosis. In general, there is an inverse relation between NYHA class and 6MWD, with mean values of approximately 400, 320, and 225 meters for classes II, III, and IV, respectively. Decreased 6MWT performance is also associated with an increased risk of hospitalization and mortality. In patients with heart failure, the 6MWD is more responsive to symptomatic deterioration than improvement.

The 6MWT also correlates with actual physical activity levels in patients with peripheral arterial disease, and it appears to be more so than treadmill testing.

In general terms, the minimal clinically important 6MWD change for patients with either cardiac or pulmonary disease is in the range of 14.0 to 30.5 meters.

While not affecting the organ systems involved in exercise directly, other conditions independently associated with a negative 6MWT performance in relation to the stage of the disease include chronic liver disease and renal failure.

Enhancing Healthcare Team Outcomes

Since test performance mainly reflects the integrated activity of the heart and lungs, information derived from the test will be relevant to assessing the degree of impairment associated with conditions affecting either or both of these organs. Therefore, pulmonologists and cardiologists will often be the clinicians requesting the 6MWT and using the data obtained. Other healthcare professionals that may use the 6MWT include primary care providers and anesthesiologists as part of preoperative risk assessments or in the general evaluation of patients with COPD.

Modified reference equations are available for use in offices with limited space. Considering the value that clinicians in a broad range of specialties can derive from this test, practitioners, in general, should be familiarized with it and the implications of abnormal results.

Proper training of respiratory therapists, nurses, medical assistants, and other personnel conducting the test is an essential aspect of the procedure. Without their dedicated participation through its performance, the test may not be conducted reliably or safely. Accurate and timely notification to the ordering or supervising providers of test results or complications will improve patient outcomes and safety.


Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, Wanger J, MacIntyre N, Kaminsky DA, Culver BH, Revill SM, Hernandes NA, Andrianopoulos V, Camillo CA, Mitchell KE, Lee AL, Hill CJ, Singh SJ. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014 Dec;44(6):1428-46. [PubMed]
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 01;166(1):111-7. [PubMed]
Santos BF, Souza HC, Miranda AP, Cipriano FG, Gastaldi AC. Performance in the 6-minute walk test and postoperative pulmonary complications in pulmonary surgery: an observational study. Braz J Phys Ther. 2016 Jan-Feb;20(1):66-72. [PMC free article] [PubMed]
Celli B, Tetzlaff K, Criner G, Polkey MI, Sciurba F, Casaburi R, Tal-Singer R, Kawata A, Merrill D, Rennard S., COPD Biomarker Qualification Consortium. The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016 Dec 15;194(12):1483-1493. [PMC free article] [PubMed]
Aalstad LT, Hardie JA, Espehaug B, Thorsen E, Bakke PS, Eagan TML, Frisk B. Lung hyperinflation and functional exercise capacity in patients with COPD – a three-year longitudinal study. BMC Pulm Med. 2018 Dec 06;18(1):187. [PMC free article] [PubMed]
du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011 May 01;183(9):1231-7. [PubMed]
Martin C, Chapron J, Hubert D, Kanaan R, Honoré I, Paillasseur JL, Aubourg F, Dinh-Xuan AT, Dusser D, Fajac I, Burgel PR. Prognostic value of six minute walk test in cystic fibrosis adults. Respir Med. 2013 Dec;107(12):1881-7. [PubMed]
Baughman RP, Lower EE. Six-minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med. 2007 Sep;13(5):439-44. [PubMed]
Shah MR, Hasselblad V, Gheorghiade M, Adams KF, Swedberg K, Califf RM, O’Connor CM. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2001 Nov 01;88(9):987-93. [PubMed]
McDermott MM, Guralnik JM, Criqui MH, Liu K, Kibbe MR, Ferrucci L. Six-minute walk is a better outcome measure than treadmill walking tests in therapeutic trials of patients with peripheral artery disease. Circulation. 2014 Jul 01;130(1):61-8. [PMC free article] [PubMed]
Bellet RN, Adams L, Morris NR. The 6-minute walk test in outpatient cardiac rehabilitation: validity, reliability and responsiveness–a systematic review. Physiotherapy. 2012 Dec;98(4):277-86. [PubMed]
Pankoff BA, Overend TJ, Lucy SD, White KP. Reliability of the six-minute walk test in people with fibromyalgia. Arthritis Care Res. 2000 Oct;13(5):291-5. [PubMed]
Falvo MJ, Earhart GM. Six-minute walk distance in persons with Parkinson disease: a hierarchical regression model. Arch Phys Med Rehabil. 2009 Jun;90(6):1004-8. [PubMed]
Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008 Apr;14(3):383-90. [PubMed]
Montes J, McDermott MP, Martens WB, Dunaway S, Glanzman AM, Riley S, Quigley J, Montgomery MJ, Sproule D, Tawil R, Chung WK, Darras BT, De Vivo DC, Kaufmann P, Finkel RS., Muscle Study Group and the Pediatric Neuromuscular Clinical Research Network. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010 Mar 09;74(10):833-8. [PMC free article] [PubMed]
Ko V, Naylor JM, Harris IA, Crosbie J, Yeo AE. The six-minute walk test is an excellent predictor of functional ambulation after total knee arthroplasty. BMC Musculoskelet Disord. 2013 Apr 24;14:145. [PMC free article] [PubMed]
Jenkins S, Čečins N. Six-minute walk test: observed adverse events and oxygen desaturation in a large cohort of patients with chronic lung disease. Intern Med J. 2011 May;41(5):416-22. [PubMed]
Enright PL. The six-minute walk test. Respir Care. 2003 Aug;48(8):783-5. [PubMed]
Britto RR, Probst VS, de Andrade AF, Samora GA, Hernandes NA, Marinho PE, Karsten M, Pitta F, Parreira VF. Reference equations for the six-minute walk distance based on a Brazilian multicenter study. Braz J Phys Ther. 2013 Nov-Dec;17(6):556-63. [PMC free article] [PubMed]
Chetta A, Zanini A, Pisi G, Aiello M, Tzani P, Neri M, Olivieri D. Reference values for the 6-min walk test in healthy subjects 20-50 years old. Respir Med. 2006 Sep;100(9):1573-8. [PubMed]
Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1384-7. [PubMed]
Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med. 1997 Apr;155(4):1278-82. [PubMed]
Chuang ML, Lin IF, Wasserman K. The body weight-walking distance product as related to lung function, anaerobic threshold and peak VO2 in COPD patients. Respir Med. 2001 Jul;95(7):618-26. [PubMed]
du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014 May;43(5):1421-9. [PubMed]
Giannitsi S, Bougiakli M, Bechlioulis A, Kotsia A, Michalis LK, Naka KK. 6-minute walking test: a useful tool in the management of heart failure patients. Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719870084. [PMC free article] [PubMed]
Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review. J Eval Clin Pract. 2017 Apr;23(2):377-381. [PubMed]
Alameri HF, Sanai FM, Al Dukhayil M, Azzam NA, Al-Swat KA, Hersi AS, Abdo AA. Six Minute Walk Test to assess functional capacity in chronic liver disease patients. World J Gastroenterol. 2007 Aug 07;13(29):3996-4001. [PMC free article] [PubMed]
Bučar Pajek M, Čuk I, Leskošek B, Mlinšek G, Buturović Ponikvar J, Pajek J. Six-Minute Walk Test in Renal Failure Patients: Representative Results, Performance Analysis and Perceived Dyspnea Predictors. PLoS One. 2016;11(3):e0150414. [PMC free article] [PubMed]
Keeratichananont W, Thanadetsuntorn C, Keeratichananont S. Value of preoperative 6-minute walk test for predicting postoperative pulmonary complications. Ther Adv Respir Dis. 2016 Feb;10(1):18-25. [PMC free article] [PubMed]
Beekman E, Mesters I, Gosselink R, Klaassen MP, Hendriks EJ, Van Schayck OC, de Bie RA. The first reference equations for the 6-minute walk distance over a 10 m course. Thorax. 2014 Sep;69(9):867-8. [PubMed]

Disclosure: Harold Matos Casano declares no relevant financial relationships with ineligible companies.

Disclosure: Fatima Anjum declares no relevant financial relationships with ineligible companies.

This entry was posted in Cardiopulmonary Rehabilitation, Six Minute Walk Test. Bookmark the permalink.